SARS-CoV-2 Vaccines and Multiple Sclerosis: An Update

Area of Science:

• Immunology
• Neurology
• Vaccinology

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, has led to a global health crisis with significant mortality.
• Emerging SARS-CoV-2 variants, particularly Omicron sublines, have become dominant globally.
• Understanding the immune response to SARS-CoV-2 vaccines in individuals with multiple sclerosis (MS) on disease-modifying therapies (DMTs) is crucial.

Purpose of the Study:

• To provide an updated overview of COVID-19 vaccines for patients with multiple sclerosis (MS).
• To offer recommendations for clinical practice concerning MS and SARS-CoV-2 vaccination.
• To address vaccine efficacy, safety, SARS-CoV-2 variants, vaccine hesitancy, and immune response in MS patients on DMTs.

Main Methods:

• This study is a review of existing literature and clinical data.
• It synthesizes evidence on SARS-CoV-2 vaccine performance in the context of multiple sclerosis.
• The review focuses on immune responses modulated by various disease-modifying therapies.

Main Results:

• Evidence suggests varying immune responses to SARS-CoV-2 vaccines among MS patients on different DMTs.
• Safety profiles of COVID-19 vaccines in MS populations require careful consideration.
• The emergence of SARS-CoV-2 variants necessitates ongoing evaluation of vaccine effectiveness.

Conclusions:

• Updated clinical recommendations are needed for optimizing COVID-19 vaccination strategies in MS patients.
• Personalized approaches considering DMTs and individual immune responses are essential.
• Further research is warranted to fully elucidate vaccine efficacy and long-term safety in this population.